| pubmed-article:21315280 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21315280 | lifeskim:mentions | umls-concept:C0011923 | lld:lifeskim |
| pubmed-article:21315280 | lifeskim:mentions | umls-concept:C0531004 | lld:lifeskim |
| pubmed-article:21315280 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:21315280 | lifeskim:mentions | umls-concept:C0032743 | lld:lifeskim |
| pubmed-article:21315280 | lifeskim:mentions | umls-concept:C0597354 | lld:lifeskim |
| pubmed-article:21315280 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:21315280 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:21315280 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:21315280 | pubmed:dateCreated | 2011-2-14 | lld:pubmed |
| pubmed-article:21315280 | pubmed:abstractText | Fatty acid amide hydrolase (FAAH) is the enzyme responsible for metabolising the endogenous cannabinoid, anandamide, and thus represents an important target for molecular imaging. To date, no radiotracer has been shown to be useful for imaging of FAAH using either positron emission tomography (PET) or single photon emission computed tomography (SPECT). We here determine the suitability of a novel carbon-11-labeled inhibitor of FAAH via ex vivo biodistribution studies in rat brain in conjunction with pharmacological challenges. | lld:pubmed |
| pubmed-article:21315280 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21315280 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21315280 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21315280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21315280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21315280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21315280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21315280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21315280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21315280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21315280 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21315280 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21315280 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:21315280 | pubmed:issn | 1872-9614 | lld:pubmed |
| pubmed-article:21315280 | pubmed:author | pubmed-author:PartonD EDE | lld:pubmed |
| pubmed-article:21315280 | pubmed:author | pubmed-author:HouleSylvainS | lld:pubmed |
| pubmed-article:21315280 | pubmed:author | pubmed-author:WilsonAlan... | lld:pubmed |
| pubmed-article:21315280 | pubmed:author | pubmed-author:VasdevNeilN | lld:pubmed |
| pubmed-article:21315280 | pubmed:author | pubmed-author:GarciaArmando... | lld:pubmed |
| pubmed-article:21315280 | pubmed:author | pubmed-author:TongJunchaoJ | lld:pubmed |
| pubmed-article:21315280 | pubmed:copyrightInfo | Copyright © 2011 Elsevier Inc. All rights reserved. | lld:pubmed |
| pubmed-article:21315280 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21315280 | pubmed:volume | 38 | lld:pubmed |
| pubmed-article:21315280 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21315280 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21315280 | pubmed:pagination | 247-53 | lld:pubmed |
| pubmed-article:21315280 | pubmed:meshHeading | pubmed-meshheading:21315280... | lld:pubmed |
| pubmed-article:21315280 | pubmed:meshHeading | pubmed-meshheading:21315280... | lld:pubmed |
| pubmed-article:21315280 | pubmed:meshHeading | pubmed-meshheading:21315280... | lld:pubmed |
| pubmed-article:21315280 | pubmed:meshHeading | pubmed-meshheading:21315280... | lld:pubmed |
| pubmed-article:21315280 | pubmed:meshHeading | pubmed-meshheading:21315280... | lld:pubmed |
| pubmed-article:21315280 | pubmed:meshHeading | pubmed-meshheading:21315280... | lld:pubmed |
| pubmed-article:21315280 | pubmed:meshHeading | pubmed-meshheading:21315280... | lld:pubmed |
| pubmed-article:21315280 | pubmed:meshHeading | pubmed-meshheading:21315280... | lld:pubmed |
| pubmed-article:21315280 | pubmed:meshHeading | pubmed-meshheading:21315280... | lld:pubmed |
| pubmed-article:21315280 | pubmed:meshHeading | pubmed-meshheading:21315280... | lld:pubmed |
| pubmed-article:21315280 | pubmed:meshHeading | pubmed-meshheading:21315280... | lld:pubmed |
| pubmed-article:21315280 | pubmed:meshHeading | pubmed-meshheading:21315280... | lld:pubmed |
| pubmed-article:21315280 | pubmed:meshHeading | pubmed-meshheading:21315280... | lld:pubmed |
| pubmed-article:21315280 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21315280 | pubmed:articleTitle | [11C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography. | lld:pubmed |
| pubmed-article:21315280 | pubmed:affiliation | PET Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. alan.wilson@camhpet.ca | lld:pubmed |
| pubmed-article:21315280 | pubmed:publicationType | Journal Article | lld:pubmed |
